Sweden sounds the alarm on loneliness
Roro Wirlander Beydoun, 40, manages a pharmacy in downtown Örebro, a city of 160,000 people located 200 kilometers west of Stockholm. The pharmacy employs about 15 staff. Since March 1, Beydoun has dedicated one hour of his working time each month to fighting loneliness – his own, and that of his loved ones or his customers. In addition to continuing to pay his salary, the Apotek Hjärtat chain, which owns his pharmacy, gives him 1,000 Swedish kronor (about €90) to organize various activities.
11 employees from the group, which has 4,000 staff members in Sweden, joined this pilot project called " vanvard" ("caring for friends") – a nod to the " friskvard" ("health care") program that allows employers to fund sports activities for their employees. The idea emerged as part of an effort to tackle involuntary isolation, which the liberal-conservative government has declared a national cause for the duration of its term, allocating 300 million kronor (€27 million) annually since 2023.
"Every day, in our pharmacies across Sweden, we meet people who feel lonely and we see the consequences of this involuntary loneliness on their lives. Just as we would with other illnesses, we want to help fight it," explained Monika Magnusson, head of Apotek Hjärtat. A study conducted by the Public Health Agency of Sweden in 2022 found that 24% of people affected by loneliness suffered from severe mental health disorders, and 28% had suicidal thoughts. With this project, Magnusson said, the pharmacy chain is aiming to raise awareness among its staff and among the wider public.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
a day ago
- Euronews
Hormones used by parents can cause genital changes in children
At least a dozen children in Sweden have developed unexpected physical changes after being accidentally exposed to hormone gels and sprays in recent years, health officials told Euronews Health. In one case, a ten-month-old girl in Sweden developed an enlarged clitoris that resembled a small penis after lying on the chest of her father, who was using a testosterone gel. In another case, a 10-year-old boy began growing breasts after exposure to his mother's hormone treatment. These cases have been reported by clinicians at Sahlgrenska University Hospital in Gothenburg, Sweden, who are warning parents who use topical hormone medications to avoid direct contact after applying their treatments. Hormone medications contain sex hormones that our bodies start to produce at puberty. Topical treatments, such as gels, creams, and sprays, are prescribed to adults with hormone-related disorders, patients who have finished chemotherapy, and others. But there's a risk, the Swedish doctors said, that children can absorb the hormones through skin-to-skin contact with adults using these treatments, leading to medical complications like those reported in Gothenburg. 'Babies younger than 12 months of age have very absorbent skin,' Dr Jovanna Dahlgren, a chief physician in the department of Paediatrics at Sahlgrenska University Hospital, told Euronews Health. She added that 'we should spare the kids' from accidental exposure to highly potent sex hormones. There are other options for parents who take hormone medications. Dahlgren recommends quarterly injections for patients taking testosterone, whilst patches and vaginal tablets could be an alternative to oestrogen sprays. She also said parents can apply topical treatments to areas unlikely to come into contact with children, such as the inner thighs or upper back, and recommended people keep them in a safe area away from their child's reach. Lack of awareness despite the increasing number of cases Doctors at the Sahlgrenska University Hospital started seeing cases of hormone exposure in children around eight or nine years ago, according to Dahlgren. Endocrinologists there raised the issue with regional authorities, leading to new medical guidelines, and with a pharmaceutical company that made hormone treatments, which updated its warning labels. The growing popularity of online prescriptions may be contributing to the rise in cases, Dahlgren said. In some European countries, including Sweden, Germany, and France, telehealth platforms can legally prescribe hormones. According to Sweden's Medical Products Agency, Läkemedelsverket, there have been 12 reports of 'unintended hormone exposure affecting children' since 2019. Another two cases were reported to the European medicines regulator. But Dahlgren believes this represents only a fraction of actual toll, as those do not include any of the cases recorded at her hospital. 'Our own cases aren't represented in those numbers,' she said, 'so the real figure is certainly higher'. The hospital is now collaborating with other regional centres to map the extent of these cases nationally. The problem isn't isolated to Sweden In 2024, paediatric endocrinologists in Wales published a case series documenting children who developed early pubertal signs after exposure to hormone gels or sprays used by parents. The study included similar cases as those seen in Sweden, as well as a case of a girl with breast development and mood swings linked to her mother's use of oestrogen gel. The researchers also emphasised the mental health impact that unexpected hormone exposure can have on both children and their parents, who often feel guilty. Earlier this year, a Swedish trade magazine for medical professionals reported that globally there were 41 reports of suspected secondary exposure in children and adults involving oestrogen-containing medications between 2018 and 2025, and 66 reports linked to testosterone-containing products between 2004 and 2025. Follow-up care varies depending on the severity and duration of exposure. For example, the infant girl with clitoris enlargement in Sweden recovered fully after the exposure ended. However, some young patients with repeated exposure for a long period of time need to be followed until they are adults, Dahlgren said. For instance, the 10-year-old boy with unusual breast growth is now awaiting breast reduction surgery, and his bone growth could also be disrupted due to accelerated bone age. 'We have to think about the long-term effects,' Dahlgren said. These hormones 'are steroids and act directly on the DNA, changing protein expression across the body'. She cautions that long-term exposure to testosterone can increase risks of blood clots, heart attack, stroke, and even cancer in adults. In children, the damage can be lifelong. 'That's why I would urge that people are aware that these hormone medications are potent,' Dahlgren said.
Euronews
22-07-2025
- Euronews
AstraZeneca pledges $50bn investment in the US amid 200% tariff fears
AstraZeneca will invest $50 billion (€42.8 bn) in the US by 2030 in a move to expand its R&D and manufacturing there, the firm announced on Monday. This comes as the pharmaceutical giant aims to reach the target of $80 billion (€68.5 bn) in revenue by 2030, with 50% of it hoped to come from the US. The announcement also comes as the Trump administration threatens tariffs of up to 200% on drugs that are produced outside of the US. The new investment announcement is in addition to the $3.5 billion (€3 bn) pledged in November 2024. According to a statement from the company, the US plays a 'critical role' in AstraZeneca's ability 'to launch 20 new medicines by the end of the decade'. What will AstraZeneca produce in the US? As part of the investment, the British-Swedish company plans to build a new multi-billion dollar manufacturing facility in the state of Virginia. This plant will focus on the production of treatments for chronic diseases and is the largest single investment into a facility the company has ever made. '[This] announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally,' Pascal Soriot, Chief Executive Officer at AstraZeneca said in a statement from the company. 'I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines.' The site in Virginia will have a particular focus on producing substances which make up AstraZeneca's weight management and metabolic treatment portfolio. As well as the site in Virginia, the investment will help expand facilities and production in Massachusetts, Maryland, California, Indiana and Texas, as well as finding new sites for clinical trials. AstraZeneca already has 19 R&D, manufacturing and commercial sites in the US, and the country is the company's largest market, representing 42% of their revenue. The firm currently employs more than 18,000 people and supports 92,000 jobs across the US. The new investment announcement is expected to create tens of thousands more jobs in the coming years. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness. We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.'
Euronews
08-07-2025
- Euronews
Swiss regulator approves first malaria treatment for newborn babies
Switzerland's drug regulator has approved the world's first malaria treatment for newborn babies, clearing the way for the medicine to become available in parts of Africa where the life-threatening disease is endemic. In a late-stage clinical trial, pharmaceutical giant Novartis showed the drug was safe and effective for babies weighing less than five kilograms, which they typically reach by two months of age. Traditionally, these infants have been given either a full or half-dose of the antimalarial drug intended for babies six months or older. But because newborns do not process medicines the same way, there is a higher risk of side effects. The lack of specialised treatment – and the fact that babies are not vaccinated until they are around five months old – has left the youngest infants relatively unprotected against malaria, a mosquito-borne disease that kills about 597,000 people per year. Most deaths are among children under five years old in Africa. It's not clear exactly how many babies are affected, but in 2023, there were an estimated 36 million pregnancies in 33 African countries where malaria is widespread. About one in three mothers were infected with malaria while pregnant, raising the risk that they will pass the disease along to their newborns, according to the World Health Organization (WHO). 'Every one of those [babies] is a potential target for malaria infection,' Dr Lutz Hegemann, president of Novartis' global health programme, told Euronews Health. 'We don't want to leave any patient behind, no matter how small they are'. Eight African countries – Burkina Faso, Ivory Coast, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda – are expected to quickly approve the medicine as part of a partnership with Swissmedic, the Swiss drugs regulator. Hegemann said Novartis hopes to roll the medicine out there this autumn, with more countries to follow, on a not-for-profit basis. The medicine, known as Coartem Baby, is similar to Novartis' existing drug to treat uncomplicated malaria in young children, but it has a different dose and ratio of ingredients to prevent side effects in the youngest infants. It also has a sweet cherry flavour and can be dissolved in breast milk to make it easier to give to patients. 'These are small changes, but big steps,' Dr Quique Bassat, head of the Barcelona Institute of Global Health, told Euronews Health. While the number of newborns with malaria 'still remains relatively modest in terms of the overall burden, those cases need to be treated, and therefore we need better drugs,' he added. 'Now we have something which is perfectly suitable for that specific age group where there was a gap'. Bassat advised Novartis on the clinical trial, which was funded by the European Union and the Swedish International Development Cooperation Agency.
